Acurx Pharmaceuticals (ACXP) to Release Earnings on Tuesday

Acurx Pharmaceuticals (NASDAQ:ACXP) is expected to be announcing its earnings results before the market opens on Tuesday, March 18th. Analysts expect the company to announce earnings of ($0.18) per share for the quarter. Investors interested in listening to the company’s conference call can do so using this link.

Acurx Pharmaceuticals Stock Up 0.6 %

Shares of NASDAQ:ACXP opened at $0.46 on Friday. The business has a 50 day moving average price of $0.73 and a 200 day moving average price of $1.30. Acurx Pharmaceuticals has a twelve month low of $0.43 and a twelve month high of $3.33. The company has a market cap of $8.99 million, a price-to-earnings ratio of -0.42 and a beta of -1.71.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $12.00 target price on shares of Acurx Pharmaceuticals in a research note on Friday, January 10th.

Insider Activity at Acurx Pharmaceuticals

In other news, CEO David P. Luci purchased 49,261 shares of the business’s stock in a transaction on Monday, January 6th. The stock was purchased at an average price of $1.01 per share, with a total value of $49,753.61. Following the acquisition, the chief executive officer now directly owns 1,097,458 shares in the company, valued at approximately $1,108,432.58. The trade was a 4.70 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. 29.60% of the stock is owned by corporate insiders.

About Acurx Pharmaceuticals

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.